Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311

[1]  M. Birrer,et al.  How can molecular abnormalities influence our clinical approach. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  S. Barni,et al.  Neoadjuvant dose-dense chemotherapy for locally advanced breast cancer: a meta-analysis of published studies , 2016, Anti-cancer drugs.

[3]  B. Arun,et al.  Dose‐Dense Chemotherapy for Breast Cancer , 2012, The breast journal.

[4]  D. Berry,et al.  High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Berry,et al.  High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Nortier,et al.  Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy , 2011, Breast Cancer Research and Treatment.

[7]  C. Hudis,et al.  Dose-dense chemotherapy for breast cancer: what does the future hold? , 2010, Future oncology.

[8]  Caterina Guiot,et al.  Tumor growth instability and its implications for chemotherapy. , 2009, Cancer research.

[9]  A. Gennari.  The Impact of New Chemotherapeutic and Hormone Agents on Survival in a Population-based Cohort of Women with Metastatic Breast Cancer , 2008 .

[10]  K. Gelmon,et al.  The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancer , 2007, Cancer.

[11]  Jorma Isola,et al.  Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Farquhar,et al.  High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. , 2005, The Cochrane database of systematic reviews.

[13]  D. Berry,et al.  Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Ballestrero,et al.  Dose-dense Vinorelbine and Paclitaxel with Granulocyte Colony-stimulating Factor in Metastatic Breast Cancer Patients: Anti-tumor Activity and Peripheral Blood Progenitor Cell Mobilization Capability , 2003, Breast Cancer Research and Treatment.

[15]  D. Wickerham,et al.  Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Zalcberg,et al.  Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  G. Brufman,et al.  Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  O. S. Nielsen,et al.  Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Tattersall,et al.  Phase II study of high dose epirubicin in combination with cyclophosphamide in patients with advanced breast cancer. , 1995, Australian and New Zealand journal of medicine.

[20]  L. Norton,et al.  Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.

[21]  A. Ammon,et al.  High-dose epirubicin in combination with cyclophosphamide (HD-EC) in advanced breast cancer: final results of a dose finding study and phase II trial. , 1990, Onkologie.

[22]  I. Tannock,et al.  A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Tattersall,et al.  Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. , 1987, The New England journal of medicine.

[24]  W. Hryniuk,et al.  The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[26]  L. Norton,et al.  Predicting the course of Gompertzian growth , 1976, Nature.

[27]  H. Skipper,et al.  Kinetics of mammary tumor cell growth and implications for therapy , 1971, Cancer.

[28]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[29]  A. Tutt,et al.  3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). , 2017, Breast.

[30]  A. Tutt,et al.  3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[32]  B. Frieden,et al.  Adaptive therapy. , 2009, Cancer research.

[33]  Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Clive,et al.  Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer , 2000, Bone Marrow Transplantation.

[35]  A. Coates,et al.  On the receiving end--III. Measurement of quality of life during cancer chemotherapy. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  L. Norton,et al.  The Norton-Simon hypothesis revisited. , 1986, Cancer treatment reports.

[37]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[38]  A. Dobson,et al.  Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. , 1981, Journal of chronic diseases.